Information Provided By:
Fly News Breaks for January 10, 2017
SRPT
Jan 10, 2017 | 13:51 EDT
Piper Jaffray analyst Edward Tenthoff says Sarepta Therapeutics' Q4 Exondys 51 sales of $5.4M beat his estimate of $4.5M. The company is making good progress on reimbursement and expects payor conversions to accelerate in Q2, Tenthoff tells investors in a research note. He estimates U.S. Exondys 51 sales of $274M in 2017 with peak U.S. sales of greater than $500M. Tenthoff reiterates an Overweight rating on Sarepta with a $68 price target.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.